LEO Pharma

We're presenting at the American Academy of Dermatology Annual Meeting!? In just a few days, one of the world’s largest dermatology conferences will kick off, bringing together industry leaders, healthcare professionals, and top scientists to share groundbreaking data and discuss the latest trends??? As global leaders in medical dermatology we are excited to participate in the conference and play our part in bringing forward innovative research that will help address the more than 1,500 different skin diseases.? This year, we are proud to present a late-breaker within Chronic Hand Eczema (CHE) along with an additional poster - also in CHE, showcasing some of our newest research in medical dermatology??? Swipe below to learn more about AAD and why LEO Pharma is participating ??? #LEOPharma #AAD2025 #Dermatology #BeyondTheSkin Jacob Pontoppidan Thyssen

With a focused strategy, solid market position, innovative portfolio and committed team, we are well positioned to continue advancing the standard of care for people with skin diseases while delivering long-term, profitable growth. We are grateful to our owners, the LEO Foundation // LEO Fondet and Nordic Capital, for their strong support. #LEOPharma #AnnualResults #Dermatology

??Today, on Rare Disease Day, we highlight the significant impact of rare skin conditions. As a global leader in medical dermatology, we are committed to supporting individuals living with skin conditions – rare skin diseases being no exception.? ??That's why we've partnered with DEBRA Research, a non-profit organization dedicated to transforming scientific discoveries into practical treatments and clinical applications. Their primary focus is on developing therapies and cures for Epidermolysis Bullosa (EB), a group of rare and painful genetic skin conditions that cause the skin to become extremely fragile, tearing or blistering at the slightest touch.? Through this partnership, we aim to accelerate the development of new treatments and improve the quality of life for those affected by EB?? Together, we can make a meaningful difference in the rare disease community! #LEOPharma #RareDiseaseDay #Dermatology Jacob Pontoppidan Thyssen

??NEWS: Our 2024 sustainability statement is out! Let’s take you through the highlights?? At LEO Pharma we are committed to leaving a legacy the next generations will be proud of. To us that means bringing innovative solutions to the burden of skin diseases, while driving responsible environmental and social impact.? Our Head of ESG, DE&I and Public Affairs, Christina Dahl said “I am thrilled to see our sustainability statement come out and to share insights about the strides that we take towards a more sustainable future. It is our stepping stone towards a fully aligned CSRD report next year and I am proud of the progress the teams have made already. Furthermore, it reflects our unwavering commitment to focus not only on what results we achieve as a company, but also how we do it and with what impact – for our employees, our patients and society at large. Together, we drive meaningful change and ensure a more inclusive and resilient path forward.” Read the full sustainability statement here or swipe through below highlights??? #LEOPharma #SustainabilityStatement #ESG #BeyondTheSkin

2024 delivered strong financial results, building momentum for the year ahead.?? Looking into 2025, we predict continued growth, substantially improving our financial performance and returning to a positive net result. ?? Swipe through the financial highlights below or read the full 2024 annual report to learn more: https://lnkd.in/dUGXtfY9 #LEOPharma #FullYearResults #FinancialResults #BeyondTheSkin?

Hear from our CEO, Christophe Bourdon as he breaks down some of the key highlights from our full-year results, including how we have strengthened our pipeline and successfully implemented initiatives to further improve our financial performance. In 2025, revenue growth is projected to be 6-9% (CER) and adjusted EBITDA margin to range from 15-18%. ? A huge thank you to the more than 4,000 colleagues around the world for their relentless dedication to driving innovation and bringing treatments to the 100 million people we serve every year. ?? Read the full 2024 Annual Report to learn more: https://lnkd.in/dUGXtfY9 #LEOPharma #FullYearResults #FinancialResults #BeyondTheSkin

We have just released LEO Pharma’s full-year results! The financial progress we made in 2024 is another important milestone our transformation journey. Over the course of 2024 we managed to accomplish: ?10% revenue growth (CER) ?12% dermatology growth (CER) ?35% North America growth (CER) ?43% year-over-year adjusted EBITDA growth ? And looking into 2025 we project to: Grow revenue by 6-9% (CER) and improve our adjusted EBITDA margin to 15-18%. We will also return to positive Net Profit and Positive Free Cash Flow (ex. M&A). ? We’re off to a great start in 2025 with the announcement our strategic partnership with Gilead in January it will be a very exciting year for LEO Pharma! I'm very proud of the LEO teams for making this happen! Learn more about our achievements in 2024 and ambitions for the year ahead in our Annual Report https://lnkd.in/dYUXYb27

??NEWS: Our full-year results for 2024 are out! Let’s take you through the highlights?? ? ??Revenue grew 10% (CER) to DKK 12,453 million.? ?? Dermatology revenue grew 12% (CER) to DKK 10,008 million.? ?? North America revenue grew 35% (CER) to DKK 2,234 million.? ?Adjusted EBITDA grew 43% year-over-year to DKK 895 million?? ??In 2025, revenue growth is projected to be 6-9% (CER) and adjusted EBITDA margin to range from 15-18%? CEO Christophe Bourdon said “2024 was a year of strong progress for LEO Pharma with double-digit growth in sales and another year of significantly improved EBITDA. Additionally, we have strengthened our pipeline and successfully implemented efficiency initiatives set to substantially further improve our financial performance in 2025 and return LEO Pharma to a positive net result.” ??Read the full Annual Report to learn more about our achievements in 2024 and ambitions for the year ahead https://lnkd.in/dUGXtfY9 #LEOPharma #FullYearResults #FinancialResults #BeyondTheSkin?

Did you know our early hormone research helped pave the way for the development of?some of today’s psoriasis treatments??? ??In the late 1920s, LEO Pharma began exploring hormone research, marking a significant shift in our scientific endeavors. By 1931, they introduced two new hormone products that addressed various medical conditions such as impotence, menstruation troubles, and sterility. The company quickly moved forward with this new development, and by 1935, they had submitted their first patent applications for hormone production?? ????♂???The production involved collecting urine from pregnant women, young men, and horses to extract the necessary hormones. This practice continued for many years, with the company collecting and processing raw materials to produce high-quality, durable products. The collection of urine from pregnant women in the Greater Copenhagen Area persisted until 1992, with cycle messengers and later drivers visiting 'suppliers' to collect and replace pails of urine. Although we have since ceased hormone production, the experience gained has been instrumental in shaping LEO Pharma into the dermatology company we are today. The knowledge acquired during those early days has helped pave the way for the development of?some of today’s psoriasis treatments?? #LEOPharma #Legacy #PharmaHistory #Dermatology

??How do you maintain high quality products and timely delivery when serving 100 million people worldwide??? ? ??Hit play on the video below and hear from Kristian Sibilitz , our new Head of Technical Development & Supply, how his organization plays a vital role in ensuring we meet the needs of the people who rely on us the most – our patients?? ? #LEOPharma #Dermatology #BeyondTheSkin